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Abstract 
Background: The completion of the human genome project and the accomplished milestones in the human 
proteome project; as well as the progress made so far in computational bioinformatics and “big data” processing have 
contributed immensely to individualized/personalized medicine in the developed world.
Main body: At the dawn of precision medicine, various omics-based therapies and bioengineering can now be 
applied accurately for the diagnosis, prognosis, treatment, and risk stratification of cancer in a manner that was 
hitherto not thought possible. The widespread introduction of genomics and other omics-based approaches into 
the postgraduate training curriculum of diverse medical and dental specialties, including pathology has improved 
the proficiency of practitioners in the use of novel molecular signatures in patient management. In addition, intricate 
details about disease disparity among different human populations are beginning to emerge. This would facilitate the 
use of tailor-made novel theranostic methods based on emerging molecular evidences.
Conclusion: In this review, we examined the challenges and prospects of using currently available omics-based 
technologies vis-à-vis oral pathology as well as prompt cancer diagnosis and treatment in a resource limited setting.
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Background
As the field of oral pathology expands in Africa, 
currently emerging omics-based molecular techniques 
are, in principle, poised to improve the oral disease 
diagnosis and treatment [1–4]. Despite the vast ground 
covered by the advances in molecular and omics-based 
technologies in the developed world, there remains a 
gap in the uptake and application of these methods in 
developing countries due to existing militating factors. 
In order for Africa not be left behind in all these highly 
beneficial technologies, innovation and maximization 
of the existing infrastructure is highly required. A sine 
qua non to research and innovative discoveries is good 
record keeping; which remains sub-optimally practiced 
in most developing economies [5–9]. For example, it has 
been historically recorded that two previous presidents 
of the United States of America (Ulysses Simpson Grant 
& Stephen Grover Cleveland) were diagnosed with oral 
cancer [10, 11]; however such information is lacking on 
how many African presidents have had oral cancer in 
the past. In fact, history has it that some celebrities like 
Sigmund Freud, the father of modern psycho-analysis; 
Giacomo Puccini, a famous opera composer; and Sammy 
Davis Jr., a leading entertainer, died of head and neck 
cancer [11].
Accurate capture of disease burden in Africa would 
provide impetus for addressing prevalent early diagnosis 
and treatment monitoring bottlenecks. The emergence 
of high throughput omics based sciences in the post 
genomic era concomitantly attracts the application of 
computational biology and bioinformatics to elucidate 
various omics based data [4, 12–14]. Most challenges 
preventing the implementation of omics-based molecular 
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approaches in routine diagnostic oral pathology in Africa 
are human resources and infrastructure. Low educational 
levels; lack of disease registries; poor funding and fiscal 
policies; lack of biospecimen repositories; and political 
unrests, inter alia; have significantly impeded research 
activities in many countries in Africa [15, 16].
This paper focuses on emerging omics-based 
techniques and their diagnostic and therapeutic 
potentials and challenges in the context of a resource 
limited setting.
Main text
Historical perspectives and general diagnostic challenges
Basic biomedical laboratory sciences provides the 
scientific foundation of clinical practice and supports 
the use of novel scientific discoveries to justify 
clinical decision making [17]. However, there remains 
widespread disconnect between clinicians and basic 
medical scientists [18–21]. Granted the importance of 
the art of medicine and clinical practice [22], there is a 
significant necessity to embrace evidence based science 
in the era of precision medicine. This point was alluded 
to over a century ago by the Flexner Report of 1910 [23], 
which was employed to transform the medical education 
model in America by establishing integrated biomedical 
training systems as the gold standard. A shortage of 
needed infrastructure and manpower has fixated a 
significant proportion of medical research efforts in 
Africa on bedside practice; albeit medical practice from 
ancient Egyptian papyri has been documented for various 
aliment as early as around 2000 B.C [24–28]. Indeed, 
evidence of various primary and metastatic cancers 
has been found by paleopathological and archeological 
examination of Egyptian mummies [29–34]. Despite 
the antiquity of medical practice in Africa relative to 
other regions of the world, there still exists a paucity of 
application of novel omics-based approaches to routine 
diagnostic medical sciences.
Inequalities in social determinants of health in low and 
middle income countries such as those in sub-Saharan 
Africa constitutes a huge challenge to health care access 
[35–42]. In addition, there are ample evidences of the 
existence of ethnic-based disparities in health risks 
profile in many countries [43–47]. The prospect of using 
omics-based techniques under such daunting conditions 
in resource-limited settings is dismal. To set up the 
right atmosphere for routine diagnostic and therapeutic 
application of these merging omics-based techniques, 
systems have to be instituted to address these prevalent 
disparities in healthcare practice and access in sub-
Saharan Africa.
Globally, these are interesting times to apply omics 
technologies in order to improve human health. 
Unfortunately, the African continent is way behind in 
terms of the financial and institutional commitment 
required to successfully implement a genomics program 
for research and clinical use. Genomics is a multi-million 
dollar endeavor with far reaching implications for a 
healthy and productive continent [48]. It will unravel 
health risk, accelerate drug discoveries and motivate 
lifestyles [49, 50]. Of the sub-Sahara African nations, 
only South Africa is investing in genomics technologies 
despite the success stories reported in developed 
countries around the world. For instance, Nigeria is 
a country of about 200 million people and there is no 
genome center despite the training and collaborative 
opportunities presented through the Human Heredity 
and Health in Africa (H3Africa) Initiative (h3africa.
org/) [51], which facilitates genomic researches and 
manpower development across Africa. Other factors that 
discourage the application of molecular research and 
emerging omics-based techniques to routine diagnostic 
oral pathology practice in Africa includes: poor access 
to research journals and conferences [52]; lack of needed 
skilled manpower [53, 54]; oral pathologist-to-population 
ratio (including workload and interest) [53, 55]; lack of 
well-equipped infrastructure such as laboratories and 
clinics [56–58]; poor internet facilities [59]; unstable 
electricity/power supply [60]; unfavorable health policies 
[61–63]; poor collaborative team science [64, 65]; 
knowledge gaps/educational levels [66–68]; war/local 
unrest [69]; lack of disease registries [70]; data/record gap 
in hospitals units [70, 71]; and religious/cultural beliefs 
[72], inter alia.
Molecular diagnostic challenges
The mortality rate of oral cancer is extremely challenging 
and depends mainly on the staging of disease at diagnosis 
and commencement of treatment. Even, though the 
5-year survival rate for first stage oral cancer cases can 
be as high as 80%, the 5-year survival rate for advanced 
stages (III/IV) are dismally low (20%); Up to 50% of oral 
cancer cases globally are only detected in late stages 
[73]. Hence the use of emerging diagnostic approaches 
to improve early diagnosis and prompt commencement 
of treatment is key in reducing the high mortality of oral 
cancer.
A fundamental goal of surgical pathology is to distin-
guish benign lesions from malignant ones [74, 75]. It is 
also equally important to be able to differentiate between 
indolent and aggressive tumors [76]. The use of hematox-
ylin and eosin (H&E) staining as well as the use of vari-
ous special stains; backed with good clinicopathologic 
acumen, has partly improved the diagnosis of disease, 
albeit this is sometimes with limited diagnostic accuracy 
[77, 78]. The introduction of immunohistochemistry into 
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diagnostic pathology significantly improved the confir-
mation of diagnoses, where morphological differential 
diagnosis using H&E presented a dilemma. However, 
immunohistochemistry has been cautiously used and 
interpreted after its limitations (such as variable anti-
body reactivity, background staining, poor quantitation, 
and subjective interpretation) became apparent [78–85]. 
Another layer of complexity is added to the diagnostic 
dilemma by intratumour heterogeneity and inter-biopsy 
heterogeneity, which presupposes that multiple cancer 
molecular signals can be detected in various sampled 
regions [86, 87]. This alludes to the notion that molecu-
lar classification of disease may be complimentary and in 
some situations more important than conventional his-
topathological diagnosis based on H&E staining [88–92]. 
The advent of various omics based molecular approaches 
as described hereafter, can potentially improve the diag-
nosis and monitoring of disease, particularly in the diag-
nostic grey areas. The benefit of using multiple high 
throughput techniques in a complementary and inte-
grated manner would no doubt benefit personalized/pre-
cision medicine and the field of diagnostic oral pathology 
immensely (Fig. 1).
Current and future molecular approaches
The field of molecular biology has undergone significant 
evolution in the post-genomic era [93–97]. With the 
emergence of omics-based approaches, research capa-
bilities have expanded from low to medium throughput 
biochemistry, to interrogation of the full complement of 
biomolecules in a high throughput manner. Further, bio-
logical molecule have now been characterized in a man-
ner that was hitherto not possible [97]. A few relevant 
high throughput omics based methods are described 
hereafter as they relate to the field of oral pathology and 
cancer.
Traditional biochemistry/molecular biology
To improve the field of molecular medicine, traditional 
biochemistry has employed various approaches such 
as: electrophoresis; Western, Northern, and Southern—
blotting techniques for protein, RNA and DNA 
respectively [98]; enzyme-linked immunosorbent assay 
(ELISA) [99]; gene silencing and RNA interference 
[100]; gene cloning [101]; conventional and real-time 
qualitative polymerase chain reaction (PCR) [102]; 
karyotyping & fluorescence in  situ hybridization (FISH) 
[103]; Comparative genomic hybridization (CGH) [104]; 
and chromosomal/cytogenetic analysis [105]. However, 
many of these techniques are limited because they are 
low to medium throughput in their capabilities. These 
techniques have benefitted the field of oral pathology 
by enabling the identification of molecular markers of 
various diseases. For example, cytogenetic alterations 
such as copy number gain of 16q, 8q and loss 3p, 8p, 
9p, 4q, 5q, 13q have been found to be biomarkers for 
premalignant oral lesions; while copy number gain 
of 3q, 8q, 9q, 20q, 7p, 11q13, 5p and copy number loss 
of 3p, 9q, 21q, 5q, 13q, 18q, 8p have been found to 
characterize oral squamous cell carcinoma [106–109]. 
Molecular alterations such as microsatellite instability 
(MSI), abnormal mismatch repair protein (MMR) 
proteins MLH1, PMS2, MSH2, MSH6, and loss of 
heterozygosity (LOH) of 9p21, 3p14 have been found to 
characterize premalignant oral lesions [106–108, 110, 
111]; while perturbation of p53, EGFR/STAT, COX-2, 
NF-κB, VEGF, TGF-β/Ras pathways have been found 
in oral squamous cell carcinoma [112–114]. Identified 
potential biomarkers of metastatic oral squamous 
cell carcinoma includes E-cadherin, integrins, matrix 
metalloproteinases (MMPs), IL-8, chemokine receptor 
7 and EGFR [111]. Various fusion oncogenes have been 
used as potential biomarkers of salivary gland tumours; 
such as MYB-NF1B t(6:9)(q22-23:p23-24) for Adenoid 
cystic carcinoma [115]; CRTC1-MAML2 t(11:19)(q21-
22:p13) for low or intermediate grade Mucoepidermoid 
carcinoma [116]; ETV6-NTRK3 for Mammary analogue 
secretory Carcinoma [116, 117]; PLAG & HMGA2 for 
Pleomorphic adenoma [118, 119]; EWSR1-POU5F1 
t(6:22)(p21:q12) for high grade Mucopeidermoid 
carcinoma [116]; EWSR1-ATF1 t(12:22)(q15:q12) 
for low grade hyalinizing clear cell carcinoma [120]; 
NUT-BRD4 t(15:19)(q14:p13.1) for NUT midline 
Fig. 1 Impact of omics based molecular approaches on personal-
ized/precision medicine and the field of diagnostic oral pathology
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carcinoma [121, 122]; and MECT1-MAML2 for low 
grade Mucoepidermoid carcinoma [123]. Considering 
the impact of tradition molecular biology advances on 
diagnosis of tumors in the head and neck region, it is 
plausible that emerging high throughput omics based 
techniques would even bring greater breakthroughs to 
diagnostic oral pathology practice.
Omics based approaches
Prior to the completion of the human genome project 
(which costed billions of dollars and lasted over a decade), 
only short fragments of DNA could be sequenced 
using methods such as polymerase chain reaction and 
hybrid capture [124, 125]. However, with the advent 
of massive parallel sequencing (also known as Next 
Generation Sequencing), millions of DNA fragments 
can now be sequenced even without prior knowledge 
of the sequence [124]. With an exponential reduction 
in the cost of sequencing, Next Generation Sequencing 
(NGS) has improved the utility of various omics field in 
understanding disease specific genomes [125].
The field of genomics and sequencing also owes 
its huge success to the development of the array 
technologies, which were initially fabricated for high 
throughput genomic interrogate the transcriptional 
levels of thousands of genes in a single experiment [126, 
127]. This technology has made it possible to evaluate 
pathophysiological gene expression patterns in cells and 
tissues; as well as to identify drug targets in tissues [126]. 
Different types of arrays and their application for various 
biological functions have been discussed in details 
elsewhere [126–128].
In addition, emerging technological advances have 
provided the unique opportunity to interrogate biological 
and genomic complexity to the single-cell resolution. 
This potentially provides high throughput omics based 
data which helps to delineate tissue heterogeneity from 
a bulk population of cells; as well as diversity in complex 
microbial ecosystems [129]. Although technically 
challenging, single cell technology has been applied both 
to genomic and epigenomic analyses of diseases [129, 
130]; as well as to drug discovery and development [131].
In tandem with the ever-increasing amount of data 
generated from high throughput data, a great number 
of omics fields have emerged [132]. These omics fields 
have provided access to systems level interpretation of 
molecular processes. However these techniques requires 
robust bioinformatics and computational infrastructure 
to de-convolute and integrate the emerging data for 
clinical utility [14]. The -omics suffix indicate the analysis 
of the full complement of a specific biomolecule; as well 
as its characterization, interaction or analysis [133]. 
For example, the measurement of the full complement 
of protein in a cell, tissue, body fluid, or any biological 
system is known as proteomics; and this analogy applied 
to all other biomolecules such as lipids (lipidomics), 
genes (genomics), gene transcripts (transcriptomics), 
metabolites (metabolomics), etc. It has been notably 
demonstrated by Garcia et  al. [134], that such omics 
based techniques would benefit personalized oral 
healthcare immensely. Examples of promising application 
of different omics based approaches are described below:
Genomics Genomics techniques provide a genome-
wide access to genetic information and presents a 
robust opportunity to interrogate cancer biology in a 
high throughput manner. Genomics information have 
been used to develop databases that have enhanced our 
knowledge of the cancer genome expression greatly [135]. 
Although, genomics has attained moderate success in tar-
get oncogene and tumor suppressor gene identification; 
there remains significant challenges in the transformation 
of these targets into therapies that would improve cancer 
patient management [136]. Application of genomics to 
oral cancer diagnosis in diagnostic oral pathology would 
be greatly improved by advances in the field of dental and 
craniofacial informatics [137]. Genomic alterations have 
been identified for leukoplakia as well as in the process of 
sequential oral tumorigenesis [138]; providing molecular 
information that were hitherto unavailable.
Transcriptomics Differential transcriptomics profiling 
of oropharyngeal cancers based on human papilloma virus 
(HPV) status has been shown to provide reliable molecu-
lar signature to stratify these subtypes of head and neck 
cancer [139]. Thus permitting high throughput analyses 
of gene transcript and drawing of biological inferences on 
HPV-related oral cancer.
Genome‑wide association studies (GWAS) Genome-
wide association studies (GWAS) is an unbiased statisti-
cal approach used to identify common single nucleotide 
polymorphisms across the genome that are associated 
with complex traits. Since the early 2000s when it was 
first used, there have been over 2000 published GWAS 
studies [140]. The success of GWAS is largely dependent 
on the coverage of the genotyping panel, the minor allele 
frequency of SNPs in the investigated population and 
on clearly defined phenotypes. GWAS has been used to 
identify many novel susceptibility loci for complex traits 
including oral cancers [141].
Next generation sequencing (NGS) Deep sequenc-
ing, massively paralleled sequencing or next generation 
sequencing (NGS) is a novel DNA or RNA sequenc-
ing technology that has transformed genomic research 
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[142]. As opposed to the Sanger sequencing, this is a high 
throughput method that can be used to sequence the 
complete human genome within a day [143]. Significant 
progress in the sequencing research has led to a reduction 
in its per megabase cost, number of produced sequence 
reads per run as well as the genome diversity coverage; 
which helps to adequately elucidate complex phenotypes 
of diseases [142, 144]. NGS has been applied to understand 
oncogenic mutations in oral diseases such as ameloblasto-
mas [145, 146]. Using this method, it was discovered that 
mutations in the SMO gene encoding smoothened protein 
was commoner in maxillary ameloblastomas, while BRAF 
V600E mutations were commoner in mandibular amelo-
blastomas [145]. This has far reaching implications for 
the application of personalized medicine to the manage-
ment of ameloblastomas [146]. Molecular heterogeneity 
in head and neck cancers has also been elucidated using 
NGS methods [147].
Whole exome sequencing (WES) There is an increas-
ing confidence in our ability to understand the impact 
of identified coding variations. In addition, we are able 
to sequencing the entire protein coding regions in the 
genome also known as exome sequencing. Therefore, 
exome sequencing appears to be a promising omics 
tool for the rapid identification of functional variations. 
These thus provide an opportunity for small molecule 
development through pharmacogenomics and also serve 
as information for counselling to at-risk families with 
diseases. In recent times, exome sequencing was used to 
identify novel oral cancer genes and loci [148–151].
Epigenomics The study of stable and often heritable 
changes in gene expression patterns that are not caused 
by changes in the DNA sequence is known as epigenet-
ics [152]. Two of the most well characterized epigenetic 
alterations are histone modification and DNA methyla-
tion [153]. Beyond the genome, the complete set of epi-
genetic modifications to the cellular DNA or histones 
(epigenome) are known to play an important role in the 
etiology of diseases [154]. The epigenome plays a pivotal 
role in the regulation of chromatin activity and therefore 
affect DNA repair and gene expression [152]. Epigenomic 
alterations have been established in obesity, diabetes and 
cancer [154–156]. Adequate evidence exists, that epige-
netic dysregulations have been implicated in the patho-
genesis of oral and oropharyngeal cancers [157–161]; 
hence it is plausible that epigenomic analyses would pro-
vide better insight into oral carcinogenesis.
Microbiomics Bacterial genetics of the human oral 
microbiota has been interrogated using a combination of 
transcriptomics and microbiomics techniques [162–164]. 
This techniques is highly beneficial for understanding 
infective dental pathologies such as periodontitis, osteo-
myelitis and caries; and can be potentially applied to non-
infective diseases such as cancer as well [165, 166].
Proteomics Mass spectrometry-based quantitative pro-
teomics analysis has revealed an enhanced interferon-
related signaling pathway for oral cancer cells in  vitro, 
using labeled-mass spectrometry coupled to a high perfor-
mance liquid chromatography (HPLC) system [167]. Such 
findings required further study into the significance of 
interferon in the pathogenesis of oral squamous cell carci-
noma and may serve as a basis for development of targeted 
therapies and potential biomarkers for oral cancer.
Lipidomics One of the major breakthroughs in the field 
of lipidomics that could potentially revolutionize the field 
of surgical oral pathology is the fast, real-time mass spec-
trometry based identification of surgical margin of tis-
sues intraoperatively with the use of the i-knife [168]. This 
technique diagnosed cancer margin accurately in a more 
reliable and unbiased manner using lipidomic signatures 
that differentiated between tumor and normal areas [168]. 
This could potentially eliminate the intraoperative waiting 
time while sending surgical specimen for frozen section 
tumor margin analysis.
Metabolomics The science of metabolomics looks at 
the differential signature of metabolites in biological 
pathways in a high throughput manner. Tiziani et  al. 
[169] identified metabolomics signatures for early 
diagnosis or oral cancers using 1H-nuclear magnetic 
resonance (NMR) spectroscopy methods. This method 
could potentially be used for routine early clinical diag-
nosis of various oral cancers. Recently, the push for 
reliable non-invasive timely diagnosis of cancer has 
directed research interest in the area of exhaled breath 
analysis for early detection. Breathomics is a branch of 
metabolomics that measures the total amount of vola-
tile organic compounds (VOCs) in exhaled air [170]. 
Volatile and nonvolatile organic components of the 
exhaled air are relevant indicator of metabolic status 
for clinical diagnosis and monitoring purposes [171]. 
Various metabolic processes in the body produce VOCs 
that are released into the blood and transported to the 
lung where they are passed to the airway and exhaled. 
Acquisition and measurement of unique VOCs that 
may indicate occurrence of chronic inflammation and/
or oxidative stress are potential biomarkers for early 
cancer detection [172]. This may be a plausible non-
invasive early-stage cancer screening tool and may be 
potentially applied to the detection of head and neck 
cancers.
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Ancillary tools for omics based technology
Nanotechnology Nanotechnology is an emerging, highly 
beneficial, multidisciplinary area of research that deals 
with atomic and molecular levels of matter. Some clinical 
trials are currently directed at demonstrating the thera-
nostic efficacy of nanomaterials against chronic diseases 
such as cancer [173]. Today, nanomedicine plays a signifi-
cant role in diagnostic sciences, gene therapy, drug deliv-
ery systems, as well as in screening of populations [174, 
175]. Both the field of medicine and dentistry have ben-
efitted reasonably from therapeutic and diagnostic appli-
cations of nanomaterials [176]. Several forms of nanoma-
terials and nanotechnology methods have been used for 
the diagnosis and treatment of oral cancer. A few such 
modalities that have benefitted the field of oral pathol-
ogy and oral cancer diagnosis and treatment are Surface 
Enhanced Raman Spectroscopy (SERS) [177, 178], com-
posite organic–inorganic nanoparticles (COIN) [179, 
180] and quantum dots (QD) [177, 181]. For example, 
Raman difference spectroscopy has been demonstrated 
as a non-invasive method for oral cancer diagnosis [182]. 
There is no doubt however; that these and many other 
nanotechnology approaches would continue to enhance 
the application omics approaches to personalized medi-
cine and oral pathology.
Molecular imaging Molecular imaging is a highly ben-
eficial tool with the capacity to improve every aspects of 
cancer care. It is an in vivo imaging-based characterization 
and measurement of the key biomolecules and molecular 
events that are basic to the malignant or aberrant state 
[183]. Prior to the emergence of molecular imaging, a 
number of “gold standard” scientific approaches (such as 
ViziLite, VELscope, Trimira and OralCDx, etc.) aimed 
at oral lesion detection were fraught with inconsisten-
cies during standard routine head and neck examinations 
[184–186]. However, the establishment of integrated MRI/
PET has improved the consistency and effectiveness of ear-
lier stage cancer detection [187]. Molecular imaging such 
as positron emission tomography (PET) often integrated 
with cross sectional imaging in the form of PET/computed 
tomography (PET/CT), PET/magnetic resonance imaging 
(MRI)/MR spectroscopic imaging (MRSI), as well as opti-
cal imaging; play a vital role in cancer detection, staging 
and assessment of treatment response. The optical imag-
ing is mostly performed with the radiotracer 18F-fluoro-
2-deoxy-d-glucose [FDG], integrated with cross-sectional 
imaging in the form of PET/computed tomography (PET/
CT) [188]. PET has been said to be the leading molecu-
lar imaging approach in a clinical environment [189–191]. 
PET imaging methods have been successful in both staging 
of diverse cancers and assessment of response of tumors 
to therapy [192, 193]. Several authors have shown a sig-
nificantly higher level of sialic acid in oral cancer patients 
when compared to normal patients [194–196]. The recent 
discovery of molecular imaging-based individualized 
potential molecular tumor fingerprint has facilitated a 
rapid and effective development of theranostic drugs for 
novel treatment algorithms [197, 198]. In another study, 
the efficacy of fluorescence imaging using topically applied 
lectin-fluorophore conjugates as compared to conven-
tional tissue autofluorescence in distinguishing tumor 
from normal tissues was also investigated [199]. The results 
revealed that the changes in glycosylation could differenti-
ate normal from cancerous tissues in the oral cavity with 
high SNRs [199]. This is potentially a non-invasive screen-
ing method for premalignant and malignant oral mucosal 
tumors; and as a method for defining surgical margins and 
monitoring cellular changes over time. To further validate 
this approach for oral cancer screening, in vivo testing in 
a larger clinical cohort is needed. Not least, Nanobodies 
have also been considered as highly beneficial agent in 
molecular imaging of cancers, due to its rapid accumula-
tion in tumors, homogenous distribution; efficient blood 
clearance, high specificity, safety, high tumor signal-to-
background ratios; as well as ease of conjugation to several 
kinds of imaging techniques [200].
Future molecular concepts Several advances have 
emerged in precision and personalized medicine which 
could potentially benefit the field of oral pathology vis-
à-vis molecular oral cancer diagnostics and therapy. The 
advent of microfluidic technology [201, 202] has made it 
possible to establish a rapid multistage, multi-technique 
technology known as Lab-on a-chip [202, 203]. This has 
permitted a high turnover of requested laboratory inves-
tigations during clinical diagnosis and therapy. This tech-
nology and those mentioned above have rapidly improved 
the development of point-of-care (POC) diagnostic tools 
[204–206]. These developments may have potential appli-
cations for oral pathology and cancer management. It is 
also clear that stem cell science has improved the field 
of dentistry and oral pathology. Somatic stem cells can 
be harvested from patients and reprogrammed to form 
patient-specific induced pluripotent stem (iPS) cells [207]. 
These iPS cells can be used for recombination and regen-
erative production of maxillofacial structures for trans-
plantation and maxillofacial structure reconstruction 
[207]. On the other hand, subpopulations of cancer stems 
cells have been previously identified in head and neck can-
cers, by the application of stem cell science [208]. Such in-
depth knowledge can also provide future stem cell-based 
targeted therapies against head and neck cancers [209]. 
Quantum medicine approaches such as quantum tun-
neling [210] has been previously used in understanding 
genetic mutations in cancers [211]. A quantum mechani-
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cal approach is now being considered in the understand-
ing of the evolution of cancers [211, 212]. There is no 
doubt that these emerging molecular concepts are poised 
to play a major role in oral pathology and cancer diagno-
sis; as well as therapies in the foreseeable future.
Recommendations
Considering the immense potential benefits of omics 
based approaches in the field of oral pathology and 
cancer diagnosis in developing African regions, the 
authors make the following recommendations:
  • Government focus should be directed at funding 
Infrastructure (bridging the record gap); funding 
researchers and supporting research training 
(bridging the knowledge gap).
  • As custodians of various tissue specimens, 
pathologists must take the lead (and must not be 
passive) in the application of omics based molecular 
techniques to routine diagnostic services. Advanced 
certification and annual remedial courses are also 
recommended.
  • With favorable health policy change, omics based 
molecular approaches should be integrated into 
routine clinical practice, taking dutiful quality 
assurance (internal and external) measures.
  • There should be private sector/non-governmental 
organization (NGO) participation to make the task of 
integration of omics into oral pathology effective.
  • Reimbursement policy for oral pathologist who are 
willing to practice omics science must be favorable.
  • Legislative initiative must be available to pass this 
concept into law.
  • Scarce resources must be maximized (using mobile 
phones, internet, etc. to improve the practice of 
omics based approaches in oral pathology),
  • Viable collaborative team science established 
(sharing ideas, research, equipment and meetings) 
must be established locally, regionally, continentally 
and globally.
  • Research and Educational Networks (RENs) must 
be established using a trans/inter/multidisciplinary 
approach
  • Omics-based science and personalized medicine 
topics should be integrated into the undergraduate 
and postgraduate medical/dental training curriculum
  • There are many freely available online platforms 
that tremendously facilitate omics based 
techniques, such as the Gene Expression Ominbus 
(GEO) [213]; National Center for Biotechnology 
Information (NCBI) [214]; and The Cancer Genome 
Atlas (TCGA) [215]. Such platforms offer great 
opportunities to develop knowledge in the omics 
field and researchers should be well enlightened 
about this.
Conclusion
In the light of the aforementioned recommendations and 
the tremendous burden of cancer in Africa, healthcare 
goals needs to capture the most reliable and cost effective 
methods for screening and early diagnosis of disease. It 
is unfortunate that despite the fact that up to 80% of the 
burden of cancer is found in the low and middle income 
countries (LMIC), it only receives about 5% of the global 
spending on cancer [216]. Africa has to piggy-back and 
emulate already existing transformative “training-the-
trainer” systems in the Western world such as the: Train-
ing Residents in Genomics program (TRIG) and the 
Resident in Service Examination (RISE) practiced in the 
Americas and Western Europe [217, 218]. These pro-
grams exposes trainees to hands-on omics based molecu-
lar approaches during their residency program; and thus 
increases their confidence in requesting for and interpre-
tation of such investigations. Considering that the cost of 
genomics investigation is on the decline and that we have 
entered into the $1000 genome era [219, 220], the perti-
nent question for African oral pathologists is “are you 
ready for a genome-related clinical visits (with respect 
to their genetic risk for oral pathologies) by patients?” It 
is plausible that future histopathological reports would 
proceed beyond classic histological findings to mor-
pho-molecular findings [218]; and a good knowledge of 
omics based molecular techniques is a sine qua non for 
an astute diagnostician. Emphasis should be placed on 
the multimodality approaches for omics based diagnostic 
oral oncological practices. Although all these techniques 
improve our knowledge of disease biology in an in-depth 
manner, they are most likely to play an adjunctive/sup-
portive role rather than replacing existing pathological 
techniques in its application for improving detection and 
prognostic evaluation of head and neck cancer.
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